Aoli Wang

3.0k total citations · 2 hit papers
60 papers, 1.9k citations indexed

About

Aoli Wang is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Aoli Wang has authored 60 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 13 papers in Hematology and 11 papers in Genetics. Recurrent topics in Aoli Wang's work include Chronic Lymphocytic Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (8 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Aoli Wang is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (8 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Aoli Wang collaborates with scholars based in China, United States and United Kingdom. Aoli Wang's co-authors include Qingsong Liu, Rongbin Zhou, Hongbin He, Wei Jiang, Xianming Deng, Chao Wang, Gaolin Liang, Jin Ye, Hua Jiang and Yun Chen and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and The Science of The Total Environment.

In The Last Decade

Aoli Wang

57 papers receiving 1.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity

2018 604 citations Aoli Wang, Qingsong Liu et al. profile →
Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

2017 592 citations Aoli Wang, Qingsong Liu et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Aoli Wang	1.5k	360	239	198	177	60	1.9k
Toshikazu Hada	885 0.6×	294 0.8×	467 2.0×	329 1.7×	199 1.1×	116	2.2k
Eduard Sergienko	1.4k 0.9×	468 1.3×	224 0.9×	153 0.8×	219 1.2×	77	2.5k
Hae Jin Kee	2.3k 1.6×	555 1.5×	71 0.3×	245 1.2×	557 3.1×	77	3.5k
Wen Peng	1.5k 1.0×	262 0.7×	322 1.3×	191 1.0×	732 4.1×	60	2.8k
Sudha Ananth	1.3k 0.9×	281 0.8×	82 0.3×	235 1.2×	443 2.5×	36	2.3k
Masataka Kohno	1.2k 0.8×	542 1.5×	37 0.2×	109 0.6×	250 1.4×	79	2.3k
Hiromichi Hemmi	1.0k 0.7×	280 0.8×	83 0.3×	156 0.8×	475 2.7×	80	2.2k
Eugene O. Apostolov	480 0.3×	295 0.8×	272 1.1×	181 0.9×	74 0.4×	33	1.4k
Shinya Abe	718 0.5×	156 0.4×	41 0.2×	179 0.9×	239 1.4×	90	1.9k
Lea‐Yea Chuang	1.2k 0.8×	153 0.4×	367 1.5×	169 0.9×	408 2.3×	106	2.6k

Countries citing papers authored by Aoli Wang

Since Specialization

Citations

This map shows the geographic impact of Aoli Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aoli Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aoli Wang more than expected).

Fields of papers citing papers by Aoli Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aoli Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aoli Wang. The network helps show where Aoli Wang may publish in the future.

Co-authorship network of co-authors of Aoli Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Aoli Wang. A scholar is included among the top collaborators of Aoli Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aoli Wang. Aoli Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Yun, Fengming Zou, Yuan Yuan, et al.. (2025). Discovery of a Novel Dihydroisoquinolinone Derivative as a Potent CDK9 Inhibitor Capable of Overcoming L156F Mutant for the Treatment of Hematologic Malignancies. Journal of Medicinal Chemistry. 68(8). 8106–8123.

Li, Yan, Chao Wu, Rui Jin, et al.. (2024). Hypocrellin A from an ethnic medicinal fungus protects against NLRP3-driven gout in mice by suppressing inflammasome activation. Acta Pharmacologica Sinica. 46(4). 1016–1029. 6 indexed citations

Huang, Wen, Hong Zhou, Yiting He, et al.. (2024). A novel PDGFR inhibitor WQ-C-401 prevents pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension. Experimental Cell Research. 441(1). 114154–114154. 2 indexed citations

Chang, Yufang, et al.. (2024). Adaptive complementary sliding mode control of ship course under environmental disturbance. Ocean Engineering. 312. 119016–119016. 3 indexed citations

Mei, Husheng, Jing Yang, Bin Zhou, et al.. (2023). Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies. Signal Transduction and Targeted Therapy. 8(1). 18–18. 19 indexed citations

Wang, Junjie, Ziping Qi, Yun Wu, et al.. (2023). Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus. Signal Transduction and Targeted Therapy. 8(1). 143–143. 12 indexed citations

Wang, Aoli, et al.. (2023). Positive feedback loops between fibroblasts and the mechanical environment contribute to dermal fibrosis. Matrix Biology. 121. 1–21. 16 indexed citations

Chang, Yufang, et al.. (2023). A non-singular terminal sliding mode control of the DC microgrid with constant power loads. 43. 1–6. 1 indexed citations

Wang, Beilei, Fengming Zou, Wenliang Wang, et al.. (2023). Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor. European Journal of Medicinal Chemistry. 256. 115411–115411. 3 indexed citations

10.

Liang, Xiaofei, Fengming Zou, Ziping Qi, et al.. (2023). Discovery of Pyrazolo[1,5-a]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor. European Journal of Medicinal Chemistry. 260. 115768–115768. 5 indexed citations

11.

Zhou, Bin, Beilei Wang, Fengming Zou, et al.. (2023). Discovery of dihydropyridinone derivative as a covalent EZH2 degrader. European Journal of Medicinal Chemistry. 261. 115825–115825. 4 indexed citations

12.

Liu, Juan, Jingjing Gao, Aoli Wang, et al.. (2022). Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours. Molecular Oncology. 16(8). 1761–1774. 7 indexed citations

13.

Liang, Xiaofei, Beilei Wang, Juan Liu, et al.. (2022). Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors. European Journal of Medicinal Chemistry. 243. 114782–114782. 7 indexed citations

14.

Lu, Tingting, Fengming Zou, Xixiang Li, et al.. (2021). Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). European Journal of Pharmacology. 897. 173944–173944. 8 indexed citations

15.

Li, Feng, Xiaofei Liang, Zongru Jiang, et al.. (2020). Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. Journal of Medicinal Chemistry. 63(22). 13973–13993. 12 indexed citations

16.

Wang, Wenliang, Wenliang Wang, Zongru Jiang, et al.. (2020). All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase. Cancer Letters. 473. 130–138. 7 indexed citations

17.

Wang, Beilei, Xuesong Liu, Fengming Zou, et al.. (2020). Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants. European Journal of Medicinal Chemistry. 207. 112744–112744. 15 indexed citations

18.

Wu, Yun, Beilei Wang, Junjie Wang, et al.. (2019). Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors. Journal of Medicinal Chemistry. 62(13). 6083–6101. 13 indexed citations

19.

Liu, Xuesong, Beilei Wang, Cheng Chen, et al.. (2019). Discovery of (E)-N¹-(3-Fluorophenyl)-N³-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). Journal of Medicinal Chemistry. 62(10). 5006–5024. 16 indexed citations

20.

Liang, Xiaofei, Cheng Chen, Zongru Jiang, et al.. (2018). Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. European Journal of Medicinal Chemistry. 156. 831–846. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact